111, Inc. (YI) Company Overview

What does 111, Inc. do?

111, Inc. is a Nasdaq-listed digital healthcare company connecting pharmaceutical manufacturers, pharmacies, and consumers across China. It combines pharmaceutical distribution, B2B and B2C marketplaces, consumer e-commerce, digital marketing, and supply-chain services. The official corporate profile describes an integrated healthcare ecosystem centered on 1 Medicine Marketplace and 1 Pharmacy.

A digital bridge across the pharmacy value chain

1 Pharmacy gives independent pharmacies access to product assortment, procurement tools, logistics, selected credit, and marketplace sellers. 1 Medicine Marketplace serves consumers through direct retail and third-party merchants. Manufacturers use 111 for distribution, launches, promotional execution, and pharmacy-level data. The company is therefore a wholesaler, marketplace operator, and commercialization partner.

How does 111 make money?

111 earns money in four ways: reselling products to pharmacies, retailing products to consumers, collecting marketplace and platform fees, and providing promotional services to manufacturers. The 2025 Form 20-F explains that direct sales require inventory and fulfillment, while marketplace sellers generally manage those functions themselves.

Direct product sales still dominate

FY2025 product revenue was RMB12.471 billion, or 99.3% of total revenue; service revenue was RMB85.4 million, or 0.7%. Product sales create scale but expose 111 to procurement, inventory, logistics, and price pressure. Service revenue is small but potentially more profitable because 111 need not own every unit sold.

Why marketplace and promotional revenue matter

Management is shifting from revenue volume toward marketplace and promotional income. In Q1 2026, B2B service revenue rose 28.9% even as B2B product revenue fell 34.0%. Promotional product revenue increased 70.2%, with related gross profit up 75.0%. The mix change is early, but strategically important.

Which segments drive revenue and margin?

B2B is the revenue engine, while B2C is small but higher-margin. In FY2025, B2B produced RMB12.321 billion of revenue and RMB679.5 million of segment profit. B2C generated RMB234.8 million of revenue and RMB43.9 million of segment profit. Scale comes from pharmacy distribution; margin comes disproportionately from the consumer business.

B2B creates scale

B2B’s advantage is reach. Serving more than 500,000 pharmacies across 31 provinces gives manufacturers broad retail access and supports assortment, procurement data, and route density. Yet the FY2025 B2B segment margin was only 5.5%, so small changes in purchasing cost, mix, fulfillment, or pricing materially affect profit.

B2C is smaller but structurally higher margin

B2C benefits from retail pricing and marketplace fees, but its small base limits consolidated impact. Growth could improve mix, although competing with established digital-health and e-commerce platforms makes consumer scale expensive.

What does 111’s latest quarter show?

The quarter ended March 31, 2026 shows a company in transition. The official Q1 2026 release reported a sharp revenue decline as management reduced lower-quality product volume and pursued marketplace and asset-light operations. Faster-growing service lines were still too small to offset the contraction.

Revenue contraction reflects deliberate restructuring

Cash flow and liquidity moved the wrong way

Liquid resources fell from RMB611.3 million at December 31, 2025 to RMB396.6 million at March 31, 2026, while short-term borrowings rose to RMB257.6 million. The Q1 2026 Form 6-K therefore makes liquidity central to current analysis.

What turning points shaped 111’s strategy?

111’s history is a sequence of business-model and capital-structure changes. Each turning point altered channel mix, ownership, capital needs, or governance risk.

1. 2010
   Launched the online retail pharmacy that became 1 Medicine Marketplace.
2. 2013
   Established the offshore structure and 1 Pharmacy Technology.
3. 2016
   Introduced the consumer marketplace and commission revenue.
4. 2018
   Adopted the 111 name and completed the Nasdaq IPO.
5. 2020
   Raised RMB934.8M for a proposed domestic listing, creating later redemption claims.
6. 2022
   Obtained direct ownership of former VIEs, simplifying the structure.
7. 2025
   Exited the membership program, divested subsidiaries, and adopted warehouse partnerships.
8. 2026
   Q1 exposed lower product revenue and cash flow but faster service growth.

The 2025 pivot changed the quality-versus-scale trade-off

The 2025 pivot matters most for valuation. Management accepted lower revenue to improve economics, reduce inventory exposure, and emphasize platform services. The FY2025 results showed RMB12.556 billion of revenue, positive operating cash flow of RMB119.1 million, and non-GAAP operating income of RMB7.7 million. Q1 2026 showed that the transition remains uneven.

What gives 111 a competitive advantage?

111’s strongest resources are pharmacy reach, manufacturer relationships, operating data, and the combination of distribution with digital services. These assets support assortment, launches, pharmacy engagement, and commercialization. The Hawkeye sales tool reportedly improved coverage efficiency threefold. At December 31, 2025, 111 held 31 software copyrights, 332 registered trademarks, and 33 granted patents.

Distribution reach and data create a practical moat

Independent pharmacies are fragmented, so aggregating demand lowers search costs and broadens access. Manufacturers gain a channel that would be costly to cover individually. Transaction data can improve procurement and promotional targeting. Workflow integration, assortment familiarity, credit relationships, and fulfillment reliability create practical switching friction, even without contractual lock-in.

The moat is useful, not unassailable

111 does not disclose market share sufficient to call it dominant. Its network is valuable and difficult to replicate quickly, but buyers can compare prices and use several platforms. The moat depends on converting reach into better service, retention, and cash economics.

How financially strong is 111?

Financial strength is mixed. FY2025 showed cost control, inventory reduction, and positive operating cash flow. Q1 2026 brought weaker revenue, renewed operating losses, negative cash flow, higher short-term borrowings, and lower liquidity.

Operating discipline improved in 2025

FY2025 operating expenses fell 12.3% to RMB725.8 million. Fulfillment was RMB345.2 million, selling and marketing RMB258.6 million, G&A RMB69.5 million, and technology RMB60.4 million. GAAP operating loss narrowed to RMB2.4 million, non-GAAP operating income reached RMB7.7 million, and inventory fell to RMB998.5 million.

The balance sheet remains constrained

At March 31, 2026, liquid resources equaled about 1.54 times short-term borrowings, but this excludes the 1 Pharmacy Technology redemption burden. Approximately RMB0.95 billion sat in redeemable non-controlling interest and accrued liabilities. The company had repaid about RMB282.2 million, while holders representing 60.3% of outstanding principal had accepted restructuring terms. This legacy claim can absorb cash and constrain investment.

Who owns 111 stock, and why does control matter?

111 is public but founder-controlled. Class A shares carry one vote; Class B shares carry 15. Gang Yu and Junling Liu own all Class B shares. At March 31, 2026, their holdings represented about 41.0% of economic ownership and 91.2% of voting power.

Founder voting power dominates governance

Board oversight exists within a controlled structure

The board includes both founders, finance executive Yang Chen, and three independent directors. Independent directors lead key committees, but founder votes dominate shareholder outcomes. The official management and board pages show the overlap between leadership and control. Management quality, succession, and capital allocation therefore deserve close scrutiny.

What opportunities could improve 111’s economics?

The best opportunities use the existing network without proportionate inventory or fixed assets. Marketplace commissions, promotional services, data-enabled commercialization, and warehouse partnerships can improve revenue quality if 111 proves measurable sell-through and reliable execution.

Manufacturer commercialization is the clearest upside lever

Cravit is a useful example: Q1 2026 sales rose from 84,000 to 710,000 boxes year over year. The value lies in combining launch planning, pharmacy access, targeting, and distribution. Replicating that model across manufacturers could improve economics on the existing network.

The opportunity is operating leverage, not maximum volume. Better-margin transactions may create more value than restoring low-margin sales, provided liquidity holds.

What risks could weaken 111’s outlook?

The central risk is that restructuring reduces scale faster than fee businesses grow. Revenue declined 12.8% in FY2025 and 33.1% in Q1 2026. Continued contraction without better margins and cash flow could weaken procurement leverage, supplier relevance, and pharmacy activity. Official filings also identify competition, data obligations, PRC regulation, and key-person dependence.

Liquidity and redemption obligations are the most immediate constraints

The 1 Pharmacy Technology redemption claims arose from 2020 financing for a proposed domestic listing. Because the listing missed its deadline, investors obtained redemption rights. Even with a majority of principal restructured by Q1 2026, the obligation remains large relative to liquidity and can restrict technology, inventory, and commercialization spending.

Regulation and price transparency can compress returns

Pharmaceutical commerce faces procurement rules, price comparison, prescription controls, licensing, privacy, and cybersecurity requirements. A breach or compliance failure could disrupt operations and trust. US listing plus China-based operations also create cross-border disclosure and securities risks, increasing discount-rate and terminal-value uncertainty.

Why does 111 matter for valuation?

111 is a useful DCF case because revenue and economic value can move in opposite directions. Lower direct sales may release working capital if replaced by higher-margin services. They destroy value if network activity falls or costs cannot adjust. Forecasting must focus on revenue quality.

A DCF must separate volume from revenue quality

Comparable-company analysis needs care. 111 is a distributor by revenue mix, a marketplace by strategy, and a digital-health platform by ambition. Peer multiples must reflect service mix, cash conversion, and balance-sheet risk.

What is the key takeaway from 111, Inc. analysis?

111 has built a difficult-to-replicate digital distribution network across China’s fragmented pharmacy market. More than 500,000 pharmacies, over 490 manufacturer relationships, and nationwide reach create a credible base for marketplace and commercialization services.

The weakness is low-margin monetization. FY2025 showed better cost and inventory discipline, but Q1 2026 brought a 33.1% revenue decline, negative operating cash flow, lower liquidity, and higher borrowing. Founder control supports strategic continuity but limits outside influence.